Stepping out as a global player, a restructured Takeda enrolls 20,000-plus in new dengue PhIII in a showdown with Sanofi
Christophe Weber, president and chief executive officer of Takeda Pharmaceutical Co., speaks during the 18th Nikkei Global Management Forum in Tokyo, Japan (CREDIT: Tomohiro Ohsumi/Bloomberg via Getty Images)
Last summer, when Takeda set out to restructure its global R&D operations, CEO Christophe Weber zeroed in on four key areas: cancer, GI, CNS diseases and vaccines. Part of that commitment to vaccines included a makeover into a global player. And today the biopharma company took a big step forward in that direction with the completion of enrollment of more than 20,000 kids into a pivotal Phase III test of a new dengue vaccine.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.